Endoglin, VEGF, and its receptors in predicting metastases in endometrial carcinoma

[1]  A. Semczuk,et al.  Expression of Endoglin in Primary Endometrial Cancer , 2011, Oncology.

[2]  L. Montgomery,et al.  Vascular endothelial growth factor and its relationship to the prognosis and treatment of breast, ovarian, and cervical cancer , 2010, Angiogenesis.

[3]  Florence T. H. Wu,et al.  A systems biology perspective on sVEGFR1: its biological function, pathogenic role and therapeutic use , 2009, Journal of cellular and molecular medicine.

[4]  D. Mutch.  The new FIGO staging system for cancers of the vulva, cervix, endometrium and sarcomas , 2009 .

[5]  M. Dimopoulos,et al.  Prechemotherapy Serum Levels of CD105, Transforming Growth Factor &bgr;2, and Vascular Endothelial Growth Factor Are Associated With Prognosis in Patients With Advanced Epithelial Ovarian Cancer Treated With Cytoreductive Surgery and Platinum-Based Chemotherapy , 2009, International Journal of Gynecologic Cancer.

[6]  G. Gores,et al.  Prognostic role of vascular endothelial growth factor in hepatocellular carcinoma: systematic review and meta-analysis , 2009, British Journal of Cancer.

[7]  A. Partin,et al.  Endoglin (CD105) as a urinary and serum marker of prostate cancer , 2009, International journal of cancer.

[8]  Chiun Hsu,et al.  Serum Vascular Endothelial Growth Factor/Soluble Vascular Endothelial Growth Factor Receptor 1 Ratio Is an Independent Prognostic Marker in Pancreatic Cancer , 2008, Pancreas.

[9]  L. Ellis,et al.  Endoglin (CD105): A Marker of Tumor Vasculature and Potential Target for Therapy , 2008, Clinical Cancer Research.

[10]  G. Erdogan,et al.  Neoangiogenesis and expression of hypoxia-inducible factor 1alpha, vascular endothelial growth factor, and glucose transporter-1 in endometrioid type endometrium adenocarcinomas. , 2008, Gynecologic oncology.

[11]  J. Berek,et al.  Prognostic factors and risk of extrauterine metastases in 3867 women with grade 1 endometrioid corpus cancer. , 2008, American journal of obstetrics and gynecology.

[12]  J. Sorosky,et al.  Endometrial Cancer. Author's reply , 2008 .

[13]  Liz Y. Han,et al.  Clinical and Biological Significance of Vascular Endothelial Growth Factor in Endometrial Cancer , 2007, Clinical Cancer Research.

[14]  D. Levine,et al.  The incidence of pelvic lymph node metastasis by FIGO staging for patients with adequately surgically staged endometrial adenocarcinoma of endometrioid histology , 2007, International Journal of Gynecologic Cancer.

[15]  M. Erdem,et al.  CD105 expression is an independent predictor of survival in patients with endometrial cancer. , 2006, Gynecologic oncology.

[16]  L. Claesson‐Welsh,et al.  VEGF receptor signalling ? in control of vascular function , 2006, Nature Reviews Molecular Cell Biology.

[17]  S. Aref,et al.  Soluble VEGF/sFLt1 ratio is an independent predictor of AML patient out come. , 2005, Hematology.

[18]  Y. Soini,et al.  VEGF and Its Receptors (flt-1 and KDR/flk-1) as Prognostic Indicators in Endometrial Carcinoma , 2005, Tumor Biology.

[19]  N. Funata,et al.  Association between intratumoral free and total VEGF, soluble VEGFR-1, VEGFR-2 and prognosis in breast cancer , 2005, British Journal of Cancer.

[20]  Patrick Neven,et al.  Endometrial cancer. , 2005, Lancet.

[21]  L. Akslen,et al.  Significance of CD 105 expression for tumour angiogenesis and prognosis in endometrial carcinomas , 2003, APMIS : acta pathologica, microbiologica, et immunologica Scandinavica.

[22]  J. Silverman,et al.  Endoglin (CD105) Expression in Endometrial Carcinoma , 2003, International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists.

[23]  D. Charnock-Jones,et al.  Expression of vascular endothelial growth factor (VEGF)-D and its receptor, VEGF receptor 3, as a prognostic factor in endometrial carcinoma. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[24]  A. Harris,et al.  The angiogenic “vascular endothelial growth factor/flk‐1(KDR) receptor” pathway in patients with endometrial carcinoma , 2001, Cancer.

[25]  M. Tabata,et al.  Association of serum endoglin with metastasis in patients with colorectal, breast, and other solid tumors, and suppressive effect of chemotherapy on the serum endoglin. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[26]  A. Nakagawara,et al.  Expression of vascular endothelial growth factors (VEGF-A/VEGF-1 and VEGF-C/VEGF-2) in postmenopausal uterine endometrial carcinoma. , 2001, Gynecologic oncology.

[27]  R. Woolas,et al.  Investigation of women with endometrial carcinoma using serum vascular endothelial growth factor (VEGF) measurement , 2000, International Journal of Gynecologic Cancer.

[28]  C. N. Lee,et al.  Angiogenesis of endometrial carcinomas assessed by measurement of intratumoral blood flow, microvessel density, and vascular endothelial growth factor levels. , 2000, Obstetrics and gynecology.

[29]  Y. Saito,et al.  Prognostic significance of vascular endothelial growth factor and its receptors in endometrial carcinoma. , 2000, Gynecologic oncology.

[30]  B. Fine,et al.  VEGF, flt-1, and KDR/flk-1 as prognostic indicators in endometrial carcinoma. , 2000, Gynecologic oncology.

[31]  C. N. Lee,et al.  Serum vascular endothelial growth factor in epithelial ovarian neoplasms: correlation with patient survival. , 1999, Gynecologic oncology.

[32]  N. Ferrara.  Molecular and biological properties of vascular endothelial growth factor , 1999, Journal of Molecular Medicine.

[33]  T. Tamaya,et al.  Expressions of vascular endothelial growth factor (VEGF) and its mRNA in uterine endometrial cancers. , 1998, Cancer letters.

[34]  J. Massagué,et al.  Endoglin is a component of the transforming growth factor-beta receptor system in human endothelial cells. , 1992, The Journal of biological chemistry.

[35]  B. Bundy,et al.  Surgical pathologic spread patterns of endometrial cancer: A gynecologic oncology group study , 1987, Cancer.